Table: q1_q4_2021_prescription_drug_wac_increases , manufacturer_name like G*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000401	Galt Pharmaceuticals, LLC	09/30/2021	61825030260	Orphengesic Forte (Orphenadrine Citrate 50 mg/Aspirin 770 mg/Caffeine 60 mg) Tablets, 60 Count	08/01/2021	360.00	1950.00	None	Non-innovator Multiple Source Drug	None	1	Galt Pharmaceuticals utilizes a proprietary revenue process which includes pricing. After maintaining consistent pricing since product launch, we were recently forced to implement a price increase. This increase included impact of Covid-19, supply chain shortages and the alarming inflationary pressures being seen across the country. Additionally to these macroeconomic factors are the significant increases in fees charged by PBMs and wholesalers to offset their own responses to the same.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000029	GlaxoSmithKline	03/31/2021	58160081143	PEDIARIX 0.5ML Pre-filled Syringe; Dosage form: Injection; 1 Pack	01/01/2021	7.13	90.05	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Pricing provided reflects Federal Excise Tax. Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2021	58160081152	PEDIARIX 0.5ML Pre-filled Syringe; Dosage form: Injection; 10 Pack	01/01/2021	71.25	900.45	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Pricing provided reflects Federal Excise Tax. Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.